Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 10/20 | 0.39 |
| ▸ | PREP | P48147 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 10/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | VHL | P40337 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13285547 | 0.88 | FAP (0.40) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL13382231 | 0.84 | DPP4 (0.58) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL13259711 | 0.77 | PREP (0.43) | PREPF2 | |
| SCHEMBL13259709 | 0.77 | ATM (0.45) | ELANEITGB3ITGA2B | |
| SCHEMBL8063520 | 0.77 | ATM (0.45) | ELANEITGB3ITGA2B | |
| SCHEMBL13259710 | 0.76 | ALDH1A1 (0.54) | ELANE | |
| SCHEMBL34471493 | 0.74 | CYP1A2 (0.39) | ELANEVHL | |
| SCHEMBL8236627 | 0.73 | F2 (0.44) | ELANEF2PRSS1 | |
| SCHEMBL12605461 | 0.73 | F2 (0.44) | F2PRSS1ITGB3ITGA2B | |
| SCHEMBL16329136 | 0.73 | F2 (0.44) | F2PRSS1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226155-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226155-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-08-10 | — | — | US | disclosed |
| US-9629921-B2 | Smart pro-drugs of serine protease inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-04-25 | — | — | US | disclosed |
| US-9629921-B2 | Smart pro-drugs of serine protease inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-04-25 | — | — | US | disclosed |
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | BACH BIOSCIENCES, LLC | 2013-11-14 | — | — | US | disclosed |
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | BACH BIOSCIENCES, LLC | 2013-11-14 | — | — | US | disclosed |
| EP-2204181-A2 | Protease inhibitors | Trustees of Tufts College (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | FAP 1/4885PREP 2/4885DPP4 8/4885 |
| US-20170226155-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | FAP 1/4885PREP 2/4885DPP4 8/4885 |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | FAP 1/4885PREP 2/4885DPP4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.